Lipozem Beneficial Contribution in Human Body! Lipozem is an excellent product that has received a lot of positive reviews.

MINNEAPOLIS, March 18, 2025 (GLOBE NEWSWIRE) -- Minnesota-based global NGO MATTER announced today that its MATTER 360 ...

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the filing of its Annual Report on ...

As part of our broader growth strategy, IR-MED is actively working toward uplisting to the Nasdaq Stock Exchange, a move that we believe will enhance shareholder value and expand our reach among ...

Leerink Partners acted as exclusive financial advisor to AlloVir, and Goodwin Procter LLP served as legal counsel to AlloVir. Wilmer Cutler Pickering Hale and Dorr LLP is serving as legal counsel to ...

Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of ...

Nucleic Acid Production revenue was $41.9 million for the fourth quarter, representing a 28.8% decrease year-over-year. The revenue decrease was primarily from large GMP orders in 2023 not recurring ...

(Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek ® Guava ® Muse ® cell analyzer, creating a next-generation instrument called the Cytek ® Muse ® Micro. The ...

Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026 Pivotal Phase 3 OPERA-02 trial of palazestrant in ...